Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2024-11-12 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
113年11月法人說明會簡報 — 179520241112M002.pdf
Interim / Quarterly Report Classification · 98% confidence The document is titled "美時 2024 年第三季 營運成果報告" which translates to "Medsil 2024 Q3 Operating Results Report." It contains detailed financial data for the third quarter of 2024, including consolidated revenue, gross profit, net profit after tax, EPS, and various financial ratios. It also discusses operational highlights, market performance, acquisitions, R&D progress, and ESG ratings. The presence of comprehensive financial statements and analysis for a specific quarter indicates this is a quarterly financial report. The document length is 9511 characters, which is substantial and contains actual financial data rather than just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-11-12 Chinese
113年11月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing of scheduled investor presentations (法人說明會) with dates, times, locations, and links to presentation materials and webcast URLs. It includes references to financial and operational status presentations for specific quarters (e.g., 113年第三季, which corresponds to the third quarter). The content is clearly about investor presentations rather than full financial reports or announcements. The document length is short (1657 characters) and it mainly provides schedules and links to presentations, not the presentations themselves or detailed financial data. Therefore, the document fits best into the category of Investor Presentation (IP).
2024-11-12 Chinese
113年第3季財務報告書 — 202404_1795_AIC.pdf
Audit Report / Information Classification · 95% confidence The document is titled 'Parent-Company-Only Financial Statements With Independent Auditors’ Report For the Years Ended December 31, 2024 and 2023' and contains detailed financial statements including balance sheets, statements of comprehensive income, changes in equity, cash flows, and notes to the financial statements. It also includes an independent auditor's report from KPMG with an opinion on the financial statements, audit basis, key audit matters, and responsibilities of management and auditors. The document is comprehensive, covering a full fiscal year and includes substantive financial data and analysis. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, distinct from a full Annual Report (10-K) which would be broader and include management discussion and other sections. The document is not a brief announcement or a certification letter, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. FY 2024
2024-11-12 Chinese
113年第3季財務報告書 — 202404_1795_AIA.pdf
Annual Report Classification · 100% confidence The document is titled 'Consolidated Financial Statements With Independent Auditors’ Report For the Years Ended December 31, 2024 and 2023' and includes detailed financial statements such as balance sheets, statements of comprehensive income, changes in equity, cash flows, and notes. It also contains an independent auditor's report with an opinion on the consolidated financial statements, audit basis, key audit matters, and responsibilities of management and auditors. The content is comprehensive and includes substantive financial data and analysis for a full fiscal year, consistent with an annual report. The document length is 15,000 characters, indicating it is the full report, not just an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2024-11-12 Chinese
113年第3季財務報告書 — 202404_1795_AI3.pdf
Regulatory Filings
2024-11-12 Chinese
113年第3季財務報告書 — 202404_1795_AI1.pdf
Regulatory Filings
2024-11-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.